BR112012012000A2 - derivados de quinazolina - Google Patents

derivados de quinazolina

Info

Publication number
BR112012012000A2
BR112012012000A2 BR112012012000A BR112012012000A BR112012012000A2 BR 112012012000 A2 BR112012012000 A2 BR 112012012000A2 BR 112012012000 A BR112012012000 A BR 112012012000A BR 112012012000 A BR112012012000 A BR 112012012000A BR 112012012000 A2 BR112012012000 A2 BR 112012012000A2
Authority
BR
Brazil
Prior art keywords
quinazoline derivatives
derivatives
hsp90
medicament
diseases
Prior art date
Application number
BR112012012000A
Other languages
English (en)
Inventor
Christian Sirrenberg
Hans-Michael Eggenweiler
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112012012000A2 publication Critical patent/BR112012012000A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

patente de invenção: derivados de quinazolina. a presente invenção refere-se a novos derivados de quinazolinamida da fórmula (i), na qual r^ 1^ a r^ 4^ e x têm os significados indicados na reivindicação 1, são inibidores de hsp90 e podem ser usados para a preparação de um medicamento para o tratamento de doenças nas quais a inibição, a regulação e/ou a modulação de hsp90 desempenha uma função.
BR112012012000A 2009-11-23 2010-10-26 derivados de quinazolina BR112012012000A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009054302A DE102009054302A1 (de) 2009-11-23 2009-11-23 Chinazolinderivate
PCT/EP2010/006537 WO2011060873A1 (de) 2009-11-23 2010-10-26 Chinazolinderivate

Publications (1)

Publication Number Publication Date
BR112012012000A2 true BR112012012000A2 (pt) 2016-05-10

Family

ID=43304809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012000A BR112012012000A2 (pt) 2009-11-23 2010-10-26 derivados de quinazolina

Country Status (15)

Country Link
US (1) US8906930B2 (pt)
EP (1) EP2504314B1 (pt)
JP (1) JP5841059B2 (pt)
KR (1) KR20120101085A (pt)
CN (1) CN102648178B (pt)
AR (1) AR081117A1 (pt)
AU (1) AU2010321264B2 (pt)
BR (1) BR112012012000A2 (pt)
CA (1) CA2781380C (pt)
DE (1) DE102009054302A1 (pt)
EA (1) EA201200764A1 (pt)
ES (1) ES2548027T3 (pt)
IL (1) IL219872A (pt)
MX (1) MX2012005811A (pt)
WO (1) WO2011060873A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110133048A (ko) 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3317278B1 (en) * 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU776652B2 (en) 1999-03-12 2004-09-16 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of inhibiting a chaperone protein
EP1265913A4 (en) 2000-03-24 2004-07-14 Univ Duke CHARACTERIZATION OF LIGANDS-GRP94 INTERACTIONS AND RELATED PURIFICATION, SCREENING AND PROCESSING METHODS
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
JP2004504356A (ja) 2000-07-20 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド Ｃ型肝炎ウイルスのプロセシングおよび複製の抑制
AU9254801A (en) 2000-07-28 2002-02-13 Sloan Kettering Inst Cancer Methods for treating cell proliferative disorders and viral infections
JP4535680B2 (ja) 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規１ｈ−インダゾール化合物
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
WO2006010595A1 (en) 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20080052278A1 (en) * 2006-08-25 2008-02-28 Semdirector, Inc. System and method for modeling value of an on-line advertisement campaign
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
DE102007032739A1 (de) * 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102008061214A1 (de) * 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate

Also Published As

Publication number Publication date
EP2504314A1 (de) 2012-10-03
IL219872A (en) 2017-06-29
CN102648178B (zh) 2015-01-07
MX2012005811A (es) 2012-06-12
US20120238582A1 (en) 2012-09-20
CA2781380C (en) 2017-07-25
CA2781380A1 (en) 2011-05-26
WO2011060873A1 (de) 2011-05-26
AR081117A1 (es) 2012-06-27
DE102009054302A1 (de) 2011-05-26
JP2013511477A (ja) 2013-04-04
CN102648178A (zh) 2012-08-22
AU2010321264B2 (en) 2016-05-26
EA201200764A1 (ru) 2012-12-28
EP2504314B1 (de) 2015-08-05
AU2010321264A1 (en) 2012-07-12
KR20120101085A (ko) 2012-09-12
JP5841059B2 (ja) 2016-01-06
US8906930B2 (en) 2014-12-09
ES2548027T3 (es) 2015-10-13
IL219872A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
EA201000098A1 (ru) Производные хиназолинамида
BRPI0514295A (pt) 1, 5-difenilpirazóis
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
ATE517882T1 (de) Chinolinderivate
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
EA201100503A1 (ru) Глюкозидные производные и их применения
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
EA200802329A1 (ru) Производные триазола ii
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201100872A1 (ru) Производные хиназолинамида
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2009094560A3 (en) Thienopyranones as kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2373 DE 28-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.